Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and CD3. Linclatamig can bind to LY6G6D and CD3-positive T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research [1].
In Vitro, Linclatamig has a favorable safety profile and can be used in research on colorectal cancer[1].
References:
[1]. Fakih M, et al. Abstract CT157: Phase 1 dose-escalation study of linclatamig, a LY6G6D× CD3 T cell-engaging bispecific antibody, in patients with colorectal cancer. Cancer Research, 2025, 85(8_Supplement_2): CT157-CT157.
In Vitro, Linclatamig has a favorable safety profile and can be used in research on colorectal cancer[1].
References:
[1]. Fakih M, et al. Abstract CT157: Phase 1 dose-escalation study of linclatamig, a LY6G6D× CD3 T cell-engaging bispecific antibody, in patients with colorectal cancer. Cancer Research, 2025, 85(8_Supplement_2): CT157-CT157.